This is not completely true, as there are viral diseases where antivirals can cure the disease. For example, there are now
drugs that are able to cure 94-99% of people infected with the most common type of the hepatitis C virus. There is also evidence that
monoclonal antibody treatments against Ebola are able to cure ~90% of those infected. Similar approaches (e.g. drugs targeting the RNA polymerase like
remdesivir and monoclonal antibody cocktails like the one developed by Regeneron) are being tried against SARS-CoV-2, though the data have not been promising for either approach (see
this for remdesivir and
this for the antibody treatments).
On the broader question,
here's a good article that covers many of the points mentioned by others in the thread. Mainly, 1) viruses have fewer drug targets than bacteria because of their much smaller genomes, and 2) there are a greater variety of viruses, so there are not broad-spectrum antivirals (unlike antibiotics which can target a large range of bacteria).
For vaccines, designing a new vaccine is not terribly difficult and it can be done
quite quickly. The main bottleneck for vaccine development is testing. Because vaccines are given to a large number of healthy individuals, we need to be very careful about vaccine efficacy and safety. A vaccine that is not effective could do a lot of harm (though giving people a false sense of security) as would a vaccine with bad side effects.